SureTrader SureTrader
Home > Boards > US Listed > Medical - Equipment >

Cytosorbents Corporation (CTSO)

Add CTSO Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 9/25/2016 2:18:11 PM - Followers: 175 - Board type: Free - Posts Today: 1
About CytoSorbents, CytoSorb, and HemoDefend

CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. In 2011, CytoSorb®, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, allowing it to be sold throughout the European Union (E.U.) under the CE Mark, to be used in clinical situations where cytokines are elevated. The goal of the CytoSorb® cytokine filter is to reduce "cytokine storm" in critically-ill patients that could otherwise lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death in common illnesses such as sepsis, trauma, burn injury, acute respiratory distress syndrome, and pancreatitis. The CytoSorb® filter has demonstrated statistically significant reductions in mortality in septic patients at high risk of death in early studies and is now being sold in Germany, Austria and Switzerland for the treatment of critical care illnesses, with availability in other E.U. countries planned in the future, assuming adequate and timely funding, and continued positive results from clinical studies.

HemoDefend is a development-stage blood purification technology platform for the blood transfusion industry intended to reduce transfusion reactions and safeguard the quality and safety of the blood supply. The HemoDefend technology utilizes the Company's polymer bead technology to remove many substances, such as antibodies, free hemoglobin and inflammatory mediators that can cause potentially serious and sometimes fatal transfusion reactions.

CytoSorb® and HemoDefend are just two of a number of different polymers the Company has designed for various medical applications, including improved dialysis, reduction of post-surgical complications in cardiac surgery, treatment of inflammatory and autoimmune disorders, radio-imaging contrast removal in imaging and interventional radiology procedures, and the treatment of rhabdomyolysis, drug overdose, and others. Additional information is available for download on the Company's website:


CytoSorb® - A First-in-Class Cytokine Filter Approved in the European Union


CytoSorb® is a potentially breakthrough critical care immunotherapy that attempts to address one of the most challenging unmet medical needs in medicine…the ability to prevent or mitigate multiple organ failure - the leading cause of death in the intensive care unit (ICU) from any cause.

In response to life-threatening conditions such as sepsis and infection, trauma, serious burn injuries, severe lung injury, and pancreatitis, the body frequently overreacts and produces a massive excess of cytokines, or “cytokine storm”. Cytokines normally help the body cope with injury, but at these levels, cytokine storm is toxic to the body, driving severe inflammation and a cascade of pathophysiologic changes in the body that cause cell damage, organ failure and often death. It follows that reduction of cytokine storm may limit this cascade of events, thereby reducing the severity of illness, and helping patients recover and survive. Until recently, however, there were no effective ways to reduce cytokine storm broadly.

CytoSorb® is a first-in-class extracorporeal cytokine filter, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated. It is compatible with standard hemodialysis machines and blood pumps found in most hospitals. Blood is pumped out of the body, through the CytoSorb® cartridge that contains the company’s proprietary blood compatible porous polymer beads, and the “purified” blood is recirculated back to the patient. In a six hour period, a patient's entire blood volume can be treated approximately 20 times.

CytoSorb® is clinically proven to reduce cytokine storm in the company's multi-center, randomized, controlled European Sepsis Trial conducted in Germany. Treatment was safe and well-tolerated in more than 300 human treatments in very sick patients with the worst forms of sepsis and lung injury, and treatment has been safe in nearly 1,500 human treatments overall. Early data suggests that CytoSorb® can reduce organ injury and improve survival in patients at high risk of cytokine injury, particularly those patients with very high cytokine levels, and patients older than age 65.

CytoSorb® has now been used successfully in many conditions where deadly inflammation can lead to organ injury and failure. We are seeing strong interest in the following clinical applications:


There are more than 100 key opinion leaders in Germany, Austria, and Switzerland (our direct sales territories) who are either using or committed to using CytoSorb in clinical practice or clinical studies. More than 30 investigator-initiated studies in a diverse set of applications are being planned, with many already enrolling patients. In the United States, the U.S. Air Force is funding a 30-patient, FDA-approved randomized controlled human trauma pilot study.

As these other independent studies progress, CytoSorbents collaborates with Dr. John Kellum at the University of Pittsburgh Medical Center, and is sponsoring clinical studies in the area of severe sepsis and septic shock, the result of an overzealous immune response to a severe infection such as pneumonia or a ruptured appendix. Severe sepsis and septic shock are collectively a top ten cause of death worldwide, afflicting approximately 27 million people annually, killing approximately 1 in 3 patients despite the best medical care. CytoSorbents is conducting clinical trials in Europea and currently has an FDA-approved IDE application to run a small sepsis trial in the U.S.. The company will look to conduct a U.S. pivotal sepsis study in the future as a key step towards U.S. FDA approval.

Because of the versatility of CytoSorb®, there are many other potential applications of the technology outside of critical care medicine as well. In particular, CytoSorb® has been used many times intraoperatively during open heart surgery, where the heart must be stopped in order to operate on it, while the blood is pumped outside of the body by a heart-lung machine that oxygenates the blood and pumps it back to the rest of the body. This procedure can result in the production of inflammatory mediators such as cytokines, as well as hemolysis and the release of free hemoglobin into the blood. This can result in inflammation and post-operative complications such as failure to wean from mechanical ventilation and kidney failure. There are more than 1 million open heart surgeries each year in the U.S. and E.U. combined, with an addressable market of more than $1 billion for CytoSorb®.

Another application is in cancer immunotherapy. Cancer cachexia is a wasting condition that occurs in most cancers that leads to rapid uncontrolled weight loss, anorexia, and physical debilitation. Patients lose the physical reserve needed to tolerate treatment and fight the cancer. Because CytoSorb® can remove a broad range of cytokines and other inflammatory mediators that drive cancer cachexia, it may be very helpful in this condition. CytoSorbents is exploring this application, as well as the use of CytoSorb® as a primary cancer immunotherapy to kickstart the immune system to attack cancer, with researchers at the University of Pennsylvania School of Veterinary Medicine.

CytoSorb® is being sold for clinical use in the European Union and in countries outside of the European Union that accept European CE Mark approval such as India, Russia, Turkey and others. The total addressable market for CytoSorb® in critical care applications such as sepsis, burn injury, trauma, ARDS, pancreatitis and other diseases is estimated at $10-15 Billion in the U.S. and Europe alone.


From Shareholder's Letter

Goals for 2014

We have laid out an ambitious, yet potentially achievable, agenda for the next two years. Some of our highest priorities are:

  • Greater awareness of our story and technology through increased media exposure and improved investor relations
  • Revenue growth and increased product adoption in our direct sales territories
  • Distributor agreements for CytoSorb in Europe and elsewhere
  • Strategic partnerships for our pipeline products
  • Non-dilutive funding from grants and other programs
  • Commencement of a U.S. based trial
  • Clinical data and new clinical applications with data being presented at key scientific conferences
  • Improving liquidity and institutional sponsorship of our stock with potential up-listing to a national stock exchange

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
CTSO News: CytoSorbents Expands CytoSorb® into Iran with Partner Arsak 09/23/2016 08:30:00 AM
CTSO News: CytoSorbents Sponsors Sepsis Heroes Gala in Honor of World Sepsis Day 09/15/2016 08:00:00 AM
CTSO News: Terumo Cardiovascular Group and CytoSorbents Announce CytoSorb Cardiac Surgery Partnership 09/12/2016 07:00:00 AM
CTSO News: CytoSorbents Advances War On Sepsis with Development of CytoSorb-XL 09/08/2016 07:00:00 AM
CTSO News: CytoSorbents to Present at the 2016 Rodman & Renshaw Annual Global Investment Conference 09/07/2016 07:00:00 AM
#7690   thanks for passing this on. I was showing Radhiker 09/25/16 02:18:11 PM
#7689   Arsak web site andy55q 09/23/16 07:41:36 PM
#7688   NEWS -- CytoSorbents Expands CytoSorb® into Iran with Paulness 09/23/16 09:34:26 AM
#7687   Case of the week 37/2016 andy55q 09/20/16 09:49:13 PM
#7686   NEWS -- CytoSorbents Sponsors Sepsis Heroes Gala in Paulness 09/15/16 08:33:04 AM
#7685   Great volume lately and a steady rise. I Pip611 09/14/16 08:44:00 PM
#7684   Terumo is huge Boys n girls ;-) GLA SABAI 09/12/16 02:18:12 PM
#7683   seems like a new deal every week and Pip611 09/12/16 11:55:43 AM
#7682   NEWS -- Terumo Cardiovascular Group and CytoSorbents Announce Paulness 09/12/16 09:11:51 AM
#7681   NEWS -- CytoSorbents Advances War On Sepsis with Paulness 09/08/16 07:21:39 AM
#7680   NEWS -- CytoSorbents to Present at the 2016 Paulness 09/07/16 07:52:10 AM
#7679   nice accumulation these days - maybe a run Pip611 09/06/16 01:59:18 PM
#7678   Good call....golden cross happening today! dah174174 09/06/16 01:49:01 PM
#7677   GOLDEN CROSS MA 200 & 50 next week. SABAI 09/03/16 07:57:58 AM
#7676   The Centers for Disease Control and Prevention has Canes16 09/01/16 08:11:25 AM
#7675   Simple measures cut sepsis deaths nearly in half Canes16 08/31/16 02:06:39 PM
#7674   So we are in a quiet period now? SABAI 08/30/16 02:51:21 PM
#7673   Multiple reasons to sell, only one reason to rule_rationale 08/30/16 12:55:58 PM
#7672   Insider Buying - DR. CHAN the CEO just Millstone 08/30/16 11:02:38 AM
#7671   Case of the week 34/2016 andy55q 08/30/16 10:26:36 AM
#7670   Cars, dp60 08/26/16 08:30:12 AM
#7669   Solid post. It is great to see an cars100cars 08/25/16 10:28:16 AM
#7668   All we need is one big contract from Pip611 08/25/16 07:23:31 AM
#7667   This Blood Filtering System Could Help Lower The andy55q 08/24/16 08:03:47 PM
#7666   Case of the week 33/2016 andy55q 08/24/16 07:47:06 AM
#7665   How long does this have to be above vinovista 08/19/16 01:28:03 PM
#7664   Up 4% today isn't so bad. Pip611 08/18/16 09:04:45 PM
#7663   Thanks for your contributions! Where did all of RIOgrande44 08/18/16 02:10:45 PM
#7662   We are now in Chile SA andy55q 08/18/16 10:33:02 AM
#7661   Case of the week 32/2016 andy55q 08/18/16 10:31:48 AM
#7660   I too have the impression that the filter snow 08/16/16 03:42:32 PM
#7659   But the filter is impressive. That's why im SABAI 08/16/16 02:41:19 PM
#7658   Pip But the performance was not impressive last quarter. snow 08/16/16 01:11:46 PM
#7657   Awesome conference call last week. This company has Pip611 08/15/16 08:48:24 AM
#7656   CTSO bullish 4.80 stocktrademan 08/11/16 10:26:18 AM
#7655   the internal decision was made that CytoSorb should kegparty 08/10/16 10:35:27 AM
#7654   Case of the week 31/2016 andy55q 08/10/16 07:26:47 AM
#7653   They just had a great Conf call today. Pip611 08/09/16 07:27:21 PM
#7652   This stock looks like it's been left for dead. warrenbufferzone 08/09/16 07:24:14 PM
#7651   Probabely not today but this will go nuts SABAI 08/09/16 03:48:42 PM
#7650   I'm tempering my expectations at the moment. It's exski99 08/08/16 05:35:44 PM
#7649   Does anyone expect for Fresenius to have knocked warrenbufferzone 08/08/16 02:25:15 PM
#7648   Does anyone expect tomorrow's earnings reports to be warrenbufferzone 08/08/16 01:29:03 PM
#7647   Dialysis mach. not needed. In every ER, ambulance, Murph1953 08/08/16 01:17:35 PM
#7646   NEWS -- CytoSorbents Awarded $650,000 in SBIR Grant Paulness 08/08/16 08:54:29 AM
#7645   "According to the medical team patient would presumably SABAI 08/03/16 04:08:25 PM
#7644   Case of the week 30/2016 andy55q 08/03/16 07:12:07 AM
#7643   NEWS -- CytoSorbents to Report Q2 2016 Operating Paulness 08/02/16 09:02:24 AM
#7642   Case of the week 29/2016 andy55q 07/27/16 06:44:25 AM
#7641   Case of the week 28/2016 andy55q 07/21/16 07:41:13 AM